The MarketWatch News Department was not involved in the creation of this content. -- Single-use and reusable needle-free injection devices will be designed for precise self-administration and home use ...

Single-use and reusable needle-free injection devices will be designed for precise self-administration and home use. PharmaJet injector pens are intended for needle-free subcutaneous delivery of a ...

Humira (adalimumab) is used to treat several autoimmune conditions. The drug typically stays in your system for a few months after your final dose. This article explains how long Humira may remain in ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Wegovy (semaglutide) is approved by the U.S. Food and Drug Administration (FDA) for weight loss and weight management in people with ...

The U.S. Food and Drug Administration (FDA) has designated Celltrion Inc.’s YUFLYMA (adalimumab-aaty), as an interchangeable biosimilar to Humira (adalimumab). YUFLYMA is an FDA-approved, ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the U.K. and Ireland provides ...

Switching to CT-P17 resulted in stable or increased patient satisfaction, especially for those previously on biosimilars or citrate-containing formulations. Patient education and shared ...

Owen Mumford has released a new injection pen training video. Developed in collaboration with consultant pharmacists and nursing professionals, the video addresses critical steps when clinically ...

Humira (adalimumab) treats certain types of arthritis and inflammatory diseases. This prescription drug is a liquid for injection under your skin. Humira may not be safe to receive while pregnant but ...